This page houses WEB-RADR outputs.
Work Package 1: Governance and policy
Workshop 10 December 2014 – agenda and report
Workshop 18 October 2016 – agenda and report
Publication – Social Media Monitoring and Adverse Drug Reaction Reporting in Pharmacovigilance: An Overview of the Regulatory Landscape
Coming soon: Report on the assessment of personal data protection legislation requirements (D1.3.1)
Coming soon: Ethical and data privacy recommendations in social media research and pharmacovigilance – a literature review (D1.3.2)
Coming soon: Framework for use of social media in pharmacovigilance (D1.4.1) 01 Policy on the use of mobile devices for easier, faster and more user-friendly reporting by patients, consumers and healthcare professionals and access to collected reports for signal detection purposes in the context of pharmacovigilance
Coming soon: Framework for use of social media in pharmacovigilance (D1.4.1) 02 Recommendations on the use of mobile devices for easier, faster and more user-friendly reporting by patients, consumers and healthcare professionals and access to collected reports for signal detection purposes in the context of pharmacovigilance
Coming soon: Framework for use of social media in pharmacovigilance (D1.4.2)
Coming soon: Framework for ethical considerations for the use of social media in pharmacovigilance (D1.5)
Work Package 2A: Social media
Collaborative User Interface Images
WEB-RADR Products for Social Media Monitoring
Report on Data Collection June 2015
Report on Data Collection November 2016
Report on Data Collection September 2017
Report on Language Classifiers September 2017
Work Package 2B: Analytics
Technical report describing implementation and evaluation of AE recognition in social media (D2B.1)
Technical report describing implementation and evaluation of record linkage in social media (D2B.2)
Study Summary Analytics – Record Linkage
IMI WEB-RADR Workshop Topic 6: Analysis of social media comments for pharmacovigilance purposes
WEBRADR WP2B Study Summary Analytics – Signal Detection
WEBRADR WP2B – Analytics – Signal detection Workstream
WEB-RADR WP2B Social Media Data Analysis Manual
Poster: Performance of Disproportionality Analysis for Statistical Signal Detection in Social Media Data
Work Package 3A: Mobile reporting platform
Reporting and alerting mobile application – requirements specifications
WEB-RADR WP3A Mobile app available for Second and Third Member State users
Report on Electronic Health Record Connectivity (D3A.7)
Report on changes required to the WEB RADR app to move from E2B (R2) to (R3) (D3A.8)
Yellow Card app launch, Minister George Freeman
Publication: WEB-RADR Goes Sub-Sahara, Uppsala reports
Publication: Drug-name look-up in mobile apps made easier, Uppsala reports
Work Package 3B: User based evaluation
Study 1. Qualitative evaluation of a mobile app to assess side effects
Study 2. Quantitative evaluation of a mobile app on two-way risk communication
Study 3. Assessment of experiences of WEB-RADR app users, results user experiences evaluation
Study 4. Assessment of experiences of Web-RADR app users
Pilot project patient-friendly terms
Publication: Use of a Patient-Friendly Terms List in the Adverse Drug Reaction Report Form: A Database Study
Work Package 4: Scientific Impact Evaluation
User instruction clinical quality tool (D4.3)
Clinical quality tool calculator (D4.3)
Signal detection using pharmacovigilance data from different sources (D4.9)
Publication: Social Media and Pharmacovigilance: A Review of the Opportunities and Challenges
Poster: Characteristics and Quality of Spontaneous ADR Reports Submitted via the WEB-RADR App
Work Package 5: Project management and communication
Publication: IMI Newsletter, 57th Edition – May 2016
Poster: What is WEB-RADR?
Interview: IMI interview with WEB-RADR project coordinators
General Assembly, 21 April 2016
- Event agenda
- Poster: Initial Assessment of the Utility of Social Media (WP4)
- Poster: An Example of a Rapid Response to Adverse Event shared through Social Media (WP4)
- Poster: Developement and Testing of a Clinical Documentation Tool to Assess Individual Case Safety Reports in an International Setting (WP4)
- Poster: Developement of mobile app for ADR submission (WP3A)
- Poster: Insights from Twitter Proto-AE analysis for Methylphenidate (WP4)
- Poster: Barriers and facilitators for a mobile app to report Adverse Drug Reactions and receive information about drugs (WP3B)
- Poster: Development of social media platform (WP2A)
- Poster: Work Package 1 – Governance and Policy (WP1)
Stakeholder Event, 7 September 2017
- Event agenda
- Welcome and introduction – June Raine (MHRA)
- Theme 1: Approaches to using social media for pharmacovigilance – John van Stekelenborg (Johnson & Johnson), Niklas Norén (Uppsala Monitoring Centre) and Simon Maskell (University of Liverpool). The theme 1 presentation will be released following publication of data.
- Frameworks for use of social media in pharmacovigilance – Sabine Brosch (European Medicines Agency)
- Theme 2: Using mobile technology for real-time pharmacovigilance – Stephanie Bodin-Parssinen (UCB), Peter Mol (University of Groningen), Linda Härmark (Lareb)
- Theme 3: Sustainability and future opportunities – Thee social media impact for patients – François Houÿez (EURORDIS), WEB-RADR app in Burkina Faso & Zambia – Shanthi Pal (World Health Organisation), Sustainability of WEB-RADR’s outputs – Phil Tregunno (MHRA)
- Theme 4: Maximising the value of mobile health in the new vigilance world
